Objectives: This study designed to treat iron deficiency anemia before labor using intravenous Iron Saccharate. Materials and Methods: 93.5 ± 4.7 FL 60 days' after Iron Saccharate infusion (P=0.002 (95% CI;, and the mean premedication RBCs MCH significantly increased from 24.6 ± 8.1 to 25.9 ± 5.7 pg 60 days' after Iron Saccharate infusion (P=0.0001 (95% CI; 0.51)). While, the mean premedication reticulocytes count significantly decreased from 3. 6 ± 4.2 to 0.9 ± 3.3 106/mm3 60 days' after Iron Saccharate infusion (P=0.005 (95% CI; 1.72, 2.7, 3.67) 
INTRODUCTION
The World Health Organization defines hemoglobin below 11 gm/dl as anemia. Anemia is a public health problem, and a direct cause of disability. [1] Fifty two percent of pregnant women in developing countries suffering from anemia compared to 23% in developed countries. The causes of anemia includes; iron deficiencies, poor nutrition, schistosomiasis, hookworm infestation, human immune deficiency (HIV) infection, and hemoglobinopathies. [1, 2] Maternal anemia is a leading cause of perinatal morbidity and mortality. Maternal anemia is responsible for adverse outcome in obstetrics, and increases risk of blood transfusion during the peripartum period. Iron therapy before delivery may reduce the blood transfusion rate for iron deficient women. [3] [4] [5] This study designed to treat iron deficiency anemia before labor using intravenous Iron Saccharate.
MATERIALS AND METHODS
This comparative study carried out over one year, after approval of the Ahmadi hospital ethical committee. One hundred and twenty-one (121) pregnant women, with hemoglobin level between 8-10 gm/dl due to iron deficiency anemia, who cannot tolerate oral iron preparations included in this comparative prospective study, and treated with intravenous Iron Saccharate infusion for correction of iron deficiency anemia before labor after informed consent. Pregnant women >18 years old, between 24-30 weeks` gestation, who cannot tolerate oral iron preparations with hemoglobin level between 8-10 gm/dl due to iron deficiency anemia, included in this study. Diagnosis of iron deficiency anemia during pregnancy confirmed by; hemoglobin concentration (gm/dl), serum ferritin (ug/l), MCV and MCH. Pregnant women with anemia due to other causes not related to iron deficiency excluded from this study. In addition, pregnant women received blood transfusion during current pregnancy excluded from this study. Three pregnant women excluded from this study due to parasitic infestation, and three women did not continue the treatment because of travelling and preterm delivery, so the study completed with one hundred and fifteen women (115). The intravenous iron dose calculated according to the formula; total iron needed in mg = 2.4 × prepregnancy weight in kg × (target hemoglobin concentration -actual hemoglobin concentration) gm/dl + 500 mg. Twelve (12) gm/dl was the target hemoglobin concentration, and 2.4 is a correction factor, while the 500 is the amount of stored iron in adult pregnant women. [4, 5] The calculated total intravenous iron dose was given over many sessions (6-8 sessions) , in each session 200 mg of Iron Saccharate Complex (Spimaco, Al-Qassim Pharma, Saudi Arabia) diluted in normal saline, given by an intravenous infusion over one hour every other day, and the patients were monitored during the first 15 minutes for signs of intolerance, hypotension, tackycardia or anaphylaxis. [4, 5] Iron sucrose (Iron Saccharate Complex) is stable, cleared from serum within 5-6 hours and used immediately for erythropoiesis. [6] [7] [8] Participants were asked to record any side effects following iron infusion (palpitation, arthalagia, chest or abdominal pain, headache, vertigo and skin eruptions). Oral folic acid given with intravenous iron to avoid folic deficiency. [9] Participants asked at each visit for any side effects related to intravenous iron. Treatment efficacy checked by comparing pre-medication values of; hemoglobin, reticulocytes, serum ferritin, MCV and MCH by the 60 days' post-medication values.
SAMPLE SIZE AND STATISTICAL ANALYSIS
G* Power software used for calculation of the studied sample size, statistical package for social sciences (SPSS 20) used for analysis of the results, and Student's t-test used for quantitative data analysis.
RESULTS
One hundred and twenty-one pregnant women, with hemoglobin level between 8-10 gm/dl due to iron deficiency anemia, who cannot tolerate oral iron preparations included in this study, and treated with intravenous Iron Saccharate infusion for correction of iron deficiency anemia before labor.
Three pregnant women excluded from this study due to parasitic infestation and three women did not continue the treatment because of travelling and preterm delivery, so the study completed with one hundred and fifteen women (115). Mean age of the participants was 26.2 ± 6.7, the mean parity was 1.5 ± 1.6, the mean weight was 74.3 ± 9.7, and mean gestational age was 29.2 ± 1.3 gestations. The mean premedication hemoglobin significantly increased from 8.7 ± 2.66 to 11.8 ± 2.02 gm/dl 60 days' after Iron Saccharate infusion (P=0.001 (95% CI; -3.71, -3.1, -2.48)), and the mean premedication ferritin level significantly increased from 10.7 ± 5.1 to 123.5 ± 3.9 ug/l 60 days' after Iron Saccharate infusion (P=0.002 (95% CI; -113.9, -112.8, -111.6)). Table 1 In addition; the mean premedication RBCs MCV significantly increased from 73.2 ± 6.1 to 93.5 ± 4.7 FL 60 days' after Iron Saccharate infusion (P=0.002 (95% CI; -21.70, -20.3, -18.8)), and the mean premedication RBCs MCH significantly increased from 24.6 ± 8.1 to 25.9 ± 5.7 pg 60 days' after Iron Saccharate infusion (P=0.0001 (95% CI; -3.1, -1.3, 0.51)). Table 1 While, the mean premedication reticulocytes count significantly decreased from 3.6 ± 4.2 to 0.9 ± 3.3 106/mm3 60 days' after Iron Saccharate infusion (P=0.005 (95% CI; 1.72, 2.7, 3.67)). 
DISCUSSION
Iron deficiency anemia during pregnancy deserves special attention because of its potential health hazardous. [5] Some pathologic conditions increase the risk of maternal hemorrhage, aggravate maternal anemia, and increase the need for blood transfusion. [5] One hundred and twenty-one pregnant women, with hemoglobin level between 8-10 gm/dl due to iron deficiency anemia, who cannot tolerate oral iron preparations included in this study and treated with intravenous Iron Saccharate infusion for correction of iron deficiency anemia before labor, and finally the study completed with one hundred and fifteen women (115). The mean premedication hemoglobin significantly increased from 8.7 ± 2.66 to 11.8 ± 2.02 gm/dl 60 days` after Iron Saccharate infusion, and the mean premedication ferritin level significantly increased from 10.7 ± 5.1 to 123.5 ± 3.9 ug/l 60 days` after Iron Saccharate infusion. In addition, the mean premedication RBCs MCV significantly increased from 73.2 ± 6.1 to 93.5 ± 4.7 FL 60 days` after Iron Saccharate infusion, and the mean premedication RBCs MCH significantly increased from 24.6 ± 8.1 to 25.9 ± 5.7 pg 60 days after Iron Saccharate infusion. While, the mean premedication reticulocytes count significantly decreased from 3.6 ± 4.2 to 0.9 ± 3.3 106/mm3 60 days` after Iron Saccharate infusion. Al Momen et al, found that the intravenous iron sucrose achieved significant increase in the hemoglobin levels compared to oral iron preparations (12.85 ± 6.6 versus 11.14 ± 12.4 gm/dl; respectively). [10] In This study; the only side effect recorded was metallic taste during iron infusion in 3 women (0.026%), no other side effects recorded, and the participants' compliance during iron infusion was excellent.
No major adverse effects recorded by Al Momen et al, with iron sucrose infusion, while 4 (6%) of the oral group could not tolerate oral iron, 18 (30 %) developed gastrointestinal disturbance, and they concluded that iron sucrose infusion is an effective in treatment of iron deficiency anemia than oral preparations. [10] Abhilashini et al, concluded that there were no recorded gastrointestinal adverse effects with intravenous iron, while gastrointestinal disturbance was recorded in 44% of women received oral iron. [11] Mishra et al, concluded that iron infusion is recommended for treatment of iron deficiency due to malabsorption, has a wide safety profile, and is an alternative for correction of depleted iron stores. [12] Shafi et al, found that the iron stores restored, and the hemoglobin level increased with iron sucrose infusion during pregnancy. [4] Although, Bencaivo et al, compared oral iron with intravenous iron infusion, and concluded that there was no difference between the studied groups regarding the post-therapy hemoglobin. [13] Bayoumeu et al, found that the hemoglobin level significantly increased in iron infusion group (from 9.6 ± 0.79 to 11.11 ± 1.3 gm/dl) compared to oral group (from 9.7 ± 0.5 to 11 ± 1.25 gm/dl), and serum ferritin significantly increased with iron infusion compared to oral group 30 days after iron therapy. [14] In addition, Al RA et al, found that the hemoglobin level significantly increased 14 th and 28 th , and the serum ferritin significantly increased 4 weeks after intravenous iron sucrose infusion compared to oral preparations (28 ± 26 ug/l versus 11 ± 11 ug/l; respectively). [15] Iron Saccharate Complex seems to be treatment of choice for correction of iron deficiency anemia before labor, and to avoid blood transfusion hazardous.
More studies needed in the future to evaluate the effect of Iron infusion on the fetal outcome.
Conclusion:
Iron Saccharate infusion is an effective option for correction of iron deficiency before labor in women who cannot tolerate oral iron preparations; it increases the hemoglobin, replaces the depleted iron store, and reduces the need for blood transfusion.
